157 179

Cited 5 times in

Efficacy of Intravenous Lidocaine During Endoscopic Submucosal Dissection for Gastric Neoplasm: A Randomized, Double-Blind, Controlled Study

Authors
 Ji Eun Kim  ;  Jong Bum Choi  ;  Bon-Nyeo Koo  ;  Hae Won Jeong  ;  Byung Ho Lee  ;  So Yeon Kim 
Citation
 MEDICINE, Vol.95(18) : 3593, 2016 
Journal Title
 MEDICINE 
ISSN
 0025-7974 
Issue Date
2016
MeSH
Abdominal Pain/etiology ; Abdominal Pain/prevention & control* ; Adenocarcinoma/surgery* ; Adenoma/surgery* ; Administration, Intravenous ; Aged ; Analgesics, Opioid/administration & dosage ; Anesthetics, Local/administration & dosage* ; Deep Sedation/adverse effects ; Deep Sedation/methods ; Dissection/adverse effects ; Double-Blind Method ; Female ; Fentanyl/administration & dosage ; Gastric Mucosa/surgery ; Gastroscopy/adverse effects ; Humans ; Hypnotics and Sedatives ; Lidocaine/administration & dosage* ; Male ; Middle Aged ; Pain Measurement ; Pain, Postoperative/prevention & control* ; Postoperative Nausea and Vomiting/chemically induced ; Propofol ; Stomach Neoplasms/surgery*
Abstract
Endoscopic submucosal dissection (ESD) is an advanced therapy for early gastric neoplasm and requires sedation with adequate analgesia. Lidocaine is a short-acting local anesthetic, and intravenous lidocaine has been shown to have analgesic efficacy in surgical settings. The aim of this study was to assess the effects of intravenous lidocaine on analgesic and sedative requirements for ESD and pain after ESD.Sixty-six patients scheduled for ESD randomly received either intravenous lidocaine as a bolus of 1.5 mg/kg before sedation, followed by continuous infusion at a rate of 2 mg/kg/h during sedation (lidocaine group; n = 33) or the same bolus and infusion volumes of normal saline (control group; n = 33). Sedation was achieved with propofol and fentanyl. The primary outcome was fentanyl requirement during ESD. We recorded hemodynamics and any events during ESD and evaluated post-ESD epigastric and throat pain.Fentanyl requirement during ESD reduced by 24% in the lidocaine group compared with the control group (105 ± 28 vs. 138 ± 37 μg, mean ± SD; P < 0.001). The lidocaine group reached sedation faster [40 (20-100) vs. 55 (30-120) s, median (range); P = 0.001], and incidence of patient movement during ESD decreased in the lidocaine group (3% vs. 26%, P = 0.026). Numerical rating scale for epigastric pain was significantly lower at 6 hours after ESD [2 (0-6) vs. 3 (0-8), median (range); P = 0.023] and incidence of throat pain was significantly lower in the lidocaine group (27% vs. 65%, P = 0.003). No adverse events associated with lidocaine were discovered.Administration of intravenous lidocaine reduced fentanyl requirement and decreased patient movement during ESD. Moreover, it alleviated epigastric and throat pain after ESD. Thus, we conclude that the use of intravenous adjuvant lidocaine is a new and safe sedative method during ESD.
Files in This Item:
T201601581.pdf Download
DOI
10.1097/MD.0000000000003593
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Anesthesiology and Pain Medicine (마취통증의학교실) > 1. Journal Papers
Yonsei Authors
Koo, Bon-Nyeo(구본녀) ORCID logo https://orcid.org/0000-0002-3189-1673
Kim, So Yeon(김소연) ORCID logo https://orcid.org/0000-0001-5352-157X
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/146881
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse